期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型抗精神病药:布南色林 被引量：14

A new antipsychotic agent:blonanserin
原文传递
导出
摘要 布南色林是一种新型非典型抗精神病药物,为高度选择性的5-HT2受体和多巴胺D2受体拮抗药,对多巴胺D1受体、α1肾上腺素受体、组胺H1受体和M1胆碱受体亲和力较小。该药对精神分裂症疗效明显,不良反应小,能有效改善精神分裂症患者的阴性症状、阳性症状和认知功能。本文对该药的研究进展作一综述。 Blonanserin as a new atypical antipsychotic agent is an antagonist of serotonin 5-HT2 and dopamine D2 receptor, and displays low or very low affinities for dopamine D1, adrenergic α1, histamine H1, and muscarinic M1 receptors. Blonanserin has obvious effects on schizophrenia with fewer adverse reactions. It can improve both positive and negative symptoms of schizophrenia and some aspects of cognitive function in patients with schizophrenia. The article provides an up-to-date review of the agent.
作者 常麦会 李乐华
机构地区 中南大学湘雅二医院精神卫生研究所
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2010年第8期571-575,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 精神分裂症 抗精神病药 布南色林 多巴胺拮抗药 schizophrenia antipsychotic agents blonanserin dopamine antagonists
分类号 R971.4 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1OKA M, NODA Y, OCHI Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264(1): 158-165.
  • 2EMMA D, GILLIAN M. Blonanserin: A review of its use in the management of schizophrenia[J]. CNS Drugs, 2010, 24 ( 1 ) : 65- 84.
  • 3翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量：42
  • 4MIURA S. Clinical evaluation of blonanserin for schizophrenia : a randomized study comparing blonanserin with risperidone[English abstract] [J]. Jpn J Clin Psychopharmacol, 2008, (11) : 297- 314.
  • 5HADDAD PM, SHARMA SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications[J]. CNS Drugs, 2007, 21 (11): 911-936.
  • 6RICHELSON E. Receptor pharmacology of neuroleptics: relation to clinical effects[J]. J Clin Psychiatry, 1999, 60 Suppl 10: 5- 14.
  • 7OKA M, NODA Y, OCHI Y, et ol. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264 (1): 158-165.
  • 8NODA Y, KURUMIYA S, MIURA Y, et al. Comparative study of 2- (4-ethyl-l-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta [b]pyridine (AD-5423)and haloperidol for their pharmacological activities related to antipsyehotic efficacy and/or adverse side-effects[J]. J Pharmacol Exp Ther, 1993, 265 (2) : 745 -751.
  • 9NAGAI T, NODA Y, UNE T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyelidine-induced behavioural changes in mice[J]. Neuroreport, 2003, 14 (2) : 269-272.
  • 10YOKOTA K, TATEBAYASHI H, MATSUO T, et ol. The effects of neuroleptics on the GABA-induced Cl^- current in rat dorsal root ganglion neurons: differences be tween some neuroleptics[J]. Br J Pharmacol, 2002, 135 (6): 1547-1555.

二级参考文献29

  • 1陈晋东,赵靖平,李乐华,国效峰,吴仁容,翟金国,王传跃,谢世平,高成阁,丁瑛,陈远光.阿立哌唑治疗精神分裂症的多中心随机双盲对照试验[J].中国新药与临床杂志,2005,24(11):845-848. 被引量：65
  • 2SERRETTI A,De RONCHI D,LORENZI C,et al.New antipsychotics and schizophrenia:a review on efficacy and side effects[J].Curr Med Chem,2004,11 (3):343-358.
  • 3DEAN B,SCARR E.Antipsychotic drugs:evolving mechanisms of action with improved therapeutic benefits[J].Curr Drug Targets CNS Neurol Disord,2004,3(3):217-225.
  • 4HOULTRAM B,SCANLAN M.Care maps:atypical antipsychotics.Introduction[J].Nurs Stand,2004,18 (36):42-44.
  • 5VOLAVKA J,CZOBOR P,SHEITMAN B,et al.Clozapine,olanzapine,risperidone,and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder[J].Am J Psychiatry,2002,159 (2):255-262.
  • 6BITTER I,DOSSENBACH MR,BROOK S,et al.Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry,2004,28(1):173-180.
  • 7JESTE DV,BARAK Y,MADHUSOODANAN S,et al.International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia[J].Am J Geriatr Psychiatry,2003,11 (6):638-647.
  • 8MULLEN J,JIBSON MD,SWEITZER D.A comparison of the relative safety,efficacy,and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders:the quetiapine experience with safety and tolerability(QUEST) study[J].Clin Ther,2001,23(11):1839-1854.
  • 9ARGO TR,CARNAHAN RM,PERRY PJ.Aripiprazole,a novel atypical antipsychotic drug[J].Pharmacotherapy,2004,24 (2):212-228.
  • 10POTKIN SG,SAHA AR,KUJAWA MJ,et al.Aripiprazole,an antipsychotic with a novel mechanism of action,and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder[J].Arch Gen Psychiatry,2003,60(7):681-690.

共引文献41

同被引文献101

  • 1李晓甜,曾超,冯素玲.苯溴马隆与牛血清白蛋白相互作用的研究[J].分析试验室,2010,29(5):44-47. 被引量：3
  • 2彭礼明.分散片处方、工艺特点及其进展[J].药品评价,2005,2(3):230-233. 被引量：27
  • 3杨勇,奉建芳,张慧,罗杰英.星点设计-效应面法优化蟾酥固体脂质纳米粒制备工艺[J].中国中药杂志,2006,31(8):650-653. 被引量：24
  • 4秦身钧,王建滨,姚宏伟,史长林,魏永巨.计算机辅助解析FTIR定量研究蛋白质构象的应用进展[J].河北师范大学学报（自然科学版）,2006,30(3):331-335. 被引量：7
  • 5OHNO Y, OKANO M, IMAKIJ, et at. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5 - HT 2 A an?tagonist[J]. Pharmacol Biochem Behav, 2010, 96(2) :175-180.
  • 6GARCIA E, ROBERT M, PERIS F, et al. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizo?phrenia: A randomized, double-blind, placebo-controlled, multi?centre study[J]. CNS Drugs; 2009, 23(7) :615-625.
  • 7DEEKS ED, KEATING G M. Blonanserin: a review of its use in the management of schizophrenia[J]. CNS Drugs; 2010, 24 (1) :65-84.
  • 8YANGJ, BAHK W M, CHO H S, et at. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial[J]. Clin Neuropharma?col, 2010, 33 (4) : 169-175.
  • 9DU B, ZHAO D G. The safety evaluation of ziprasidone and olanzapine in the treatment of schizophrenia[J]. 中国药学杂志,2011,46(13):1046.1048.
  • 10SUZUKI H, GEN K. The relationship between the plasma concen?tration of blonanserin, and its plasma anti -serotonin 5 - HT ( 2A ) activity/anti-dopamine D( 2) activity ratio and drug-induced ex?trapyramidal symptoms[J]. Psychiatry Clin Neurosci, 2012,66 (2) : 146-152.

引证文献14

二级引证文献35

中国新药与临床杂志
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部